Introduction Recent pivotal phase III studies in patients with advanced non-small cell lung
cancer (NSCLC) consistently showed greater survival benefit of pemetrexed in patients with …

Introduction Recent phase III studies in advanced non–small-cell lung cancer (NSCLC) have
demonstrated differential efficacy for pemetrexed according to NSCLC histology. The results …

Introduction: Recently, histology has emerged as a predictive factor for pemetrexed efficacy
in non-small cell lung cancer (NSCLC). These analyses evaluate whether the differential …

Abstract On September 26, 2008, the US Food and Drug Administration approved
pemetrexed injection (Alimta® Injection; Eli Lilly and Company, Indianapolis, IN) for use in …

Objective Pemetrexed has been approved for second-line treatment in non-small cell lung
cancer (NSCLC). However, the role of third-line pemetrexed therapy in NSCLC has not yet …

Purpose: Platinum-based regimens represent the standard first-line treatment for non-small-
cell lung cancer (SNCLC). However, newer data have established a role for pemetrexed in …

Background Subgroup analyses of randomized studies have consistently shown that
pemetrexed is exclusively effective in non-small-cell lung cancer (NSCLC) other than …

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced
Non–Small-Cell Lung Cancer: Results of th Page 1 Pemetrexed Versus Pemetrexed and …

Background The main objective of this study was to evaluate the safety of second-line
pemetrexed in Stage IIIB or IV NSCLC. Methods Overall, 95 patients received pemetrexed …

Purpose Pemetrexed is a recognized active agent for the second-line treatment for
advanced non-small cell lung cancer (NSCLC). This study was undertaken to evaluate the …